Dr. Molly Shoichet holds the Tier 1 Canada Research Chair in Tissue Engineering and is a University Professor of Chemical Engineering & Applied Chemistry, Chemistry and Biomaterials & Biomedical Engineering at the University of Toronto. She is an expert in the study of Polymers for Drug Delivery & Regeneration.
Dr. Shoichet has published over 575 papers, patents and abstracts and has given over 350 lectures worldwide. She currently leads a laboratory of 32 researchers and has graduated 157 researchers over the past 20 years. She has founded three spin-off companies from research in her laboratory.
Dr. Shoichet is the recipient of many prestigious distinctions and the only person to be a Fellow of Canada's 3 National Academies: Canadian Academy of Sciences of the Royal Society of Canada, Canadian Academy of Engineering, and Canadian Academy of Health Sciences. Dr. Shoichet won the L'Oréal-UNESCO For Women in Science Award for North America in 2015. She was elected the Foreign Member of the US National Academy of Engineering in 2016 and won the Killam Prize in Engineering in 2017. Dr. Shoichet holds the Order of Ontario, Ontario's highest honour and is a Fellow of the American Association for the Advancement of Science. In 2013, her contributions to Canada's innovation agenda and the advancement of knowledge were recognized with the QEII Diamond Jubilee Award. In 2014, she was given the University of Toronto's highest distinction, University Professor, a distinction held by less than 2% of the faculty.
Before being recruited to the University of Toronto in 1995, Dr. Shoichet worked at CytoTherapeutics Inc. on encapsulated cell therapy. Dr. Shoichet received her S.B. from the Massachusetts Institute of Technology in Chemistry (1987) and her Ph.D. from the University of Massachusetts, Amherst in Polymer Science and Engineering (1992).
DR. MOLLY SHOICHET
Order of Canada
L'Oréal-UNESCO Women in Science Award
Fellow of Canada's 3 National Academies
Meet Our Team
We are made up of world renowned researchers and experts in the biotech and startup sectors.
DR. MIKE COOKE
Mike Cooke joined Molly's laboratory in 2008 as a post-doctoral fellow to work on stem cell transplantation for recovery following stroke. This resulted in a co-first author publication in Stem Cell Reports demonstrating cells combined with HAMC could restore stroke injury in a model of stroke.
Together with Molly, Mike developed the first product for AmacaThera, a sustained analgesic for post-operative pain. This product is nearing completion of pre-clinical studies and IND enabling studies will commence in 2018. Mike pitched to both UTEST and OBIO, securing dilutive and non-dilutive seed investment for AmacaThera.
Raised dilutive and non-dilutive seed investment for AmacaThera
MR. ANDREW BISHOP
Mr. Bishop is a Partner and Co-Founder of Bingley Capital Inc., and brings over 20 years of experience in advising biotech and health care companies. He has worked on over 100 financing and M&A transactions over his career.
Prior to establishing Bingley Capital in 2009, he held senior roles in investment banking, including Head of Health Care Investment Banking at HSBC Securities (Canada) Inc., where he covered biotech, pharma, and specialty pharma companies. He started his career in investment banking focused on companies in Quebec. For the past 9 years, Mr. Bishop has also served as a Director and Chair of Willow Breast & Hereditary Cancer Support, a not-for-profit organization focused on breast and hereditary cancer.
Mr. Bishop received an International M.B.A. (Honours) from the Schulich School of Business at York University, and a Bachelor of Arts in Political Science and Economics from McGill University. He also received his Chartered Financial Analyst designation.